Abstract
Metallothioneins (MTs) may modulate a variety of cellular processes by regulating the activity of zinc-binding proteins. These proteins have been implicated in cell growth regulation, and their expression is abnormal in some tumors. In particular, MT-IIA is expressed 27-fold less in human colorectal tumors and tumor cell lines compared with normal tissue (Zhang et al., 1997). Here we demonstrate that MT-IIA downregulation occurs when human cells become immortal, a key event in tumorigenesis. After immortalization MT-IIA expression remains inducible but the basal activity of the MT-IIA promoter is decreased. MT-IIA downregulation at immortalization is one of the most common immortalization-related changes identified to date, suggesting that MT-IIA has a role in this process.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angel P, Pöting A, Mallick U, Rahmsdorf HJ, Schorpp M and Herrlich P. . 1986 Mol. Cell. Biol. 6: 1760–1766.
Bryan TM and Reddel RR. . 1994 Crit. Rev. Oncogenesis 5: 331–357.
Bryan TM, Englezou A, Gupta J, Bacchetti S and Reddel RR. . 1995 EMBO J. 14: 4240–4248.
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB and Bacchetti S. . 1992 EMBO J. 11: 1921–1929.
De Silva R and Reddel RR. . 1993 Cell. Mol. Biol. Res. 39: 101–110.
De Silva R, Whitaker NJ, Rogan EM and Reddel RR. . 1994 Exp. Cell Res. 213: 418–427.
Duncan EL and Reddel RR. . 1997 Biochem. (Moscow) 62: 1263–1274.
Garkavtsev I, Kazarov A, Gudkov A and Riabowol K. . 1996 Nature Genet. 14: 415–420.
Garkavtsev I and Riabowol K. . 1997 Mol. Cell. Biol. 17: 2014–2019.
Girardi AJ, Jensen FC and Koprowski H. . 1965 J. Cell. Comp. Physiol. 65: 69–84.
Goncharova EI and Rossman TG. . 1994 Cancer Res. 54: 5318–5323.
Hayflick L and Moorhead PS. . 1961 Exp. Cell Res. 25: 585–621.
Heguy A, West A, Richards RI and Karin M. . 1986 Mol. Cell. Biol. 6: 2149–2157.
Imbra RJ and Karin M. . 1987 Mol. Cell. Biol. 7: 1358–1363.
Jahroudi N, Foster R, Price-Haughey J, Beitel G and Gedamu L. . 1990 J. Biol. Chem. 265: 6506–6511.
Kägi JHR. . 1991 Methods Enzymol. 205: 613–626.
Karin M, Andersen RD and Herschman HR. . 1981 Eur. J. Biochem. 118: 527–531.
Karin M and Richards RI. . 1982 Nature 299: 797–802.
Karin M, Cathala G and Nguyen-Huu MC. . 1983 Proc. Natl. Acad. Sci. USA 80: 4040–4044.
Karin M, Haslinger A, Holtgreve H, Richards RI, Krauter P, Westphal HM and Beato M. . 1984 Nature 308: 513–519.
Karin M, Haslinger A, Heguy A, Dietlin T and Cooke T. . 1987 Mol. Cell. Biol. 7: 606–613.
Lechner JF and LaVeck MA. . 1985 J. Tissue Cult. Methods 9: 43–48.
Lechner JF, Tokiwa T, LaVeck M, Benedict WF, Banks-Schlegel S, Yeager H, Jr, Banerjee A and Harris CC. . 1985 Proc. Natl. Acad. Sci. USA 82: 3884–3888.
Li Y, Nichols MA, Shay JW and Xiong Y. . 1994 Cancer Res. 54: 6078–6082.
Liang P and Pardee AB. . 1992 Science 257: 967–971.
Luce MC, Schyberg JP and Bunn CL. . 1993 Exp. Gerontol. 28: 17–38.
Maclean K, Rogan EM, Whitaker NJ, Chang AC-M, Rowe PB, Dalla-Pozza L, Symonds G and Reddel RR. . 1994 Oncogene 9: 719–725.
Noble JR, Rogan EM, Neumann AA, Maclean K, Bryan TM and Reddel RR. . 1996 Oncogene 13: 1259–1268.
Öfner D, Maier H, Riedmann B, Bammer T, Rumer A, Winde G, Böcker WJ, Jasani B and Schmid KW. . 1994 Virchows Arch. 425: 491–497.
Pereira-Smith OM and Smith JR. . 1988 Proc. Natl. Acad. Sci. USA 85: 6042–6046.
Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC-M, Moy EL, Englezou A, Warneford SG, Dalla-Pozza L and Reddel RR. . 1995 Mol. Cell. Biol. 15: 4745–4753.
Schmidt CJ and Hamer DH. . 1986 Proc. Natl. Acad. Sci. USA 83: 3346–3350.
Shibanuma M, Mochizuki E, Maniwa R, Mashimo J-I, Nishiya N, Imai S-I, Takano T, Oshimura M and Nose K. . 1997 Mol. Cell. Biol. 17: 1224–1235.
Stennard FA, Holloway AF, Hamilton J and West AK. . 1994 Biochim. Biophys. Acta 1218: 357–365.
Thornalley PJ and Vasák M. . 1985 Biochim. Biophys. Acta 827: 36–44.
Udom AO and Brady FO. . 1980 Biochem. J. 187: 329–335.
Vallee BL. . 1995 Neurochem. Int. 27: 23–33.
Waalkes MP, Diwan BA, Rehm S, Ward JM, Moussa M, Cherian MG and Goyer RA. . 1996 J. Pharmacol. Exper. Therapeut. 277: 1026–1033.
West AK, Stallings R, Hildebrand CE, Chiu R, Karin M and Richards RI. . 1990 Genomics 8: 513–518.
Wilson VL and Jones PA. . 1983 Science 220: 1055–1057.
Zeng J, Heuchel R, Schaffner W and Kägi JHR. . 1991 FEBS Lett. 279: 310–312.
Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B and Kinzler KW. . 1997 Science 276: 1268–1272.
Acknowledgements
We thank Dr Adrian West for providing oligonucleotide probe sequences and plasmids, Kilian Perrem for technical assistance, and Lindy Hodgkin for help with the manuscript. This study was supported by an Australian Postgraduate Award (to ED) and the New South Wales Cancer Council Carcinogenesis Fellowship (to RR).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Duncan, E., Reddel, R. Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene 18, 897–903 (1999). https://doi.org/10.1038/sj.onc.1202370
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202370
Keywords
This article is cited by
-
Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection
Journal of Translational Medicine (2013)
-
Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma
International Journal of Colorectal Disease (2009)
-
Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma
British Journal of Cancer (2002)